Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.
Saved in:
| Title: | Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. |
|---|---|
| Authors: | Mugwagwa T; Pfizer Ltd, Tadworth, UK., Averin A; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Atwood M; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Sato R; Pfizer Inc, Collegeville, PA, USA., Vyse A; Pfizer Ltd, Tadworth, UK., Campling J; Pfizer Ltd, Tadworth, UK., Weycker D; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Slack M; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Southport, Queensland, Australia., Ellsbury G; Pfizer Ltd, Tadworth, UK., Mendes D; Pfizer Ltd, Tadworth, UK. |
| Source: | Expert review of vaccines [Expert Rev Vaccines] 2022 Sep; Vol. 21 (9), pp. 1331-1341. Date of Electronic Publication: 2022 Aug 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8395 |
|---|---|
| DOI: | 10.1080/14760584.2022.2104250 |
